Array BioPharma will collaborate with Biogen Idec for the discovery and development of inhibitors targeting a novel kinase for the treatment of autoimmune disorders. The collaboration target and lead inhibitors were discovered through Array's proprietary Kinase-Directed Phenotypic Screening Platform.
"We are encouraged by the potential of this program to address inflammatory disease and are excited to add it to our immunology research portfolio," said Jo Viney, vice-president of Immunology Research, Biogen Idec.
Under the terms of the agreement, Biogen and Array will collaborate on the discovery of the novel kinase inhibitors. Biogen will be responsible for all aspects of clinical development and commercialization. The agreement includes research funding for three years, various milestone payments payable upon achievement of certain development and commercial milestones, and royalties to Array.
Source: Array Biopharma